Atebimetinib is an investigational oral deep cyclic inhibitor that targets MEK in the MAPK pathway, which is activated in many solid tumors including pancreatic cancer. Its mechanism of action is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results